Danny Rischin, MD, on Cutaneous Squamous Cell Carcinoma: Follow-up Data on Cemiplimab

Posted: Tuesday, July 7, 2020

Danny Rischin, MD, of the Peter MacCallum Cancer Centre, discusses phase II study results showing that, for patients with advanced cutaneous squamous cell carcinoma, cemiplimab achieves overall response rates, duration of response, and survival superior to what has been reported with other agents.